Idiopathic Pulmonary Fibrosis

March 11, 2016May 13, 2016

For Idiopathic Pulmonary Fibrosis, NuQ Blood Test a Promising Diagnostic Tool

VolitionRx, dedicated to the development of blood-based diagnostic tests, recently announced preliminary data from a pilot study showing that its blood test NuQ successfully detected 86 percent of patients with ... Read more

March 8, 2016May 13, 2016

Lung Institute Opens Stem Cell Therapy Clinic in Dallas for Patients with Chronic Lung Diseases

COPD, Idiopathic Pulmonary Fibrosis, News

A top provider of stem cell therapy research for lung conditions, the Lung Institute, recently announced its new location, close to the metro Dallas area in Texas. The Institute has also ... Read more

March 4, 2016March 16, 2016

IPF Patient Survey Reveals Fear, Worry Most Commonly Experienced Emotions When Diagnosed

Idiopathic Pulmonary Fibrosis, News

An international online survey with more than 500 participants suffering from idiopathic pulmonary fibrosis (IPF) provided a picture into the real-life emotions of these patients. The survey was conducted by Germany-based Boehringer Ingelheim ... Read more

March 3, 2016March 16, 2016

Key Cause of Pulmonary Fibrosis May Be Linked to Harmful Macrophages

Idiopathic Pulmonary Fibrosis, News

Researchers at the University of Alabama at Birmingham (UAB) published a new report linking macrophages to pulmonary fibrosis (PF). Macrophages are cells that engulf toxins and harmful molecules, but in pulmonary ... Read more

February 29, 2016March 16, 2016

Inventiva, Developer of Potential Therapy for Systemic Sclerosis, Awarded at 4th World Congress for Its Innovative Approach

Idiopathic Pulmonary Fibrosis, News, Scleroderma

Inventiva, a drug discovery company focused on the treatments of fibrotic, oncological, and rare diseases, announced that the organizing committee of the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, which ... Read more

February 29, 2016May 13, 2016

Ofev (Nintedanib) Slows IPF Disease Progression, According to Analysis of Studies

Idiopathic Pulmonary Fibrosis, News

An analysis of the Phase II TOMORROW trial and two Phase III INPULSIS trials (INPULSIS-1 and INPULSIS-2), analyzing the safety and efficacy outcomes for Ofev (nintedanib, developed by Boehringer Ingelheim), revealed that ... Read more

February 26, 2016February 26, 2016

XOR-Labs Receives $2.6M to Advance Work in Improving the Quality of Donor Lungs

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, Lung Cancer, News

XENiOS, a German company specializing in medical devices for minimally invasive lung-and-heart assist, recently announced that it has invested $2.6 million in XOR-Labs Toronto, a spin-off with the potential to markedly improve the ... Read more

February 25, 2016March 16, 2016

‘Breathless’ Campaign, to Raise Awareness of IPF, Launched by Musician Joe Nichols and Boehringer Ingelheim

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals and country music artist Joe Nichols are launching a national education campaign called Breathless aimed at raising awareness for idiopathic pulmonary fibrosis (IPF), its symptoms, and the importance of ... Read more

February 23, 2016February 24, 2016

Researchers Shed Light on Idiopathic Pulmonary Fibrosis’ Impact on Patients, Caregivers

Idiopathic Pulmonary Fibrosis, News

An article published in The European Respiratory Journal used a qualitative study design to increase awareness of what it means to live with idiopathic pulmonary fibrosis (IPF), both from the patients’ ... Read more

February 23, 2016May 13, 2016

Capsugel and Pulmatrix Partnering to Develop Inhaled Therapeutics for Range of Lung Diseases

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

Capsugel and Pulmatrix, Inc., entered a partnership to advance the development and manufacture of inhaled therapeutics to treat serious pulmonary diseases, based on Pulmatrix’s iSPERSE technology. “This collaboration provides us with ... Read more